YAP1 and cancer: Furthermore, YAP inhibition via verteporfin not only impaired the oncogenic properties of HR cells and sensitized these cells to trastuzumab but also mitigated cancer cell immune evasion by downregulating PD-L1 expression and inducing ICD.